# Model List of Essential Medicines

## Adalimumab

| Section | Indications |
| --- | --- |
| Dermatological medicines > Medicines affecting skin differentiation and proliferation<br>◦ Parenteral > General injections > SC: 10 mg per 0.2 mL mL in pre-filled syringe or pre-filled pen.; 20 mg per 0.2 mL mL in pre-filled syringe or pre-filled pen.; 20 mg per 0.4 mL mL in pre-filled syringe or pre-filled pen.; 40 mg per 0.4 mL mL in pre-filled syringe or pre-filled pen.; 40 mg per 0.8 mL mL in pre-filled syringe or pre-filled pen.; 80 mg per 0.8 mL mL in pre-filled syringe or pre-filled pen. | Psoriasis of unspecified type |

## Benzoic acid + salicylic acid

| Section | Indications |
| --- | --- |
| Dermatological medicines > Antifungal medicines<br>◦ Local > Topical > Cream: 6% + 3%<br>◦ Local > Topical > Ointment: 6% + 3% | Fungal infection of the skin |

## Benzoyl peroxide

| Section | Indications |
| --- | --- |
| Dermatological medicines > Medicines affecting skin differentiation and proliferation<br>◦ Local > Topical > Cream: 5%<br>◦ Local > Topical > Lotion: 5% | Acne |

## Benzyl benzoate

| Section | Indications |
| --- | --- |
| Dermatological medicines > Scabicides and pediculicides<br>◦ Local > Topical > Lotion: 25% | Pediculosis corporis<br>Pediculosis capitis<br>Pthiriasis<br>Scabies |

## Betamethasone

| Section | Indications |
| --- | --- |
| Dermatological medicines > Anti-inflammatory and antipruritic medicines<br>◦ Local > Topical > Cream: 0.1% (as valerate)<br>◦ Local > Topical > Ointment: 0.1% (as valerate) | Dermatitis or eczema<br>Pruritus due to skin disorder<br>Psoriasis of unspecified type<br>Lichen planus |

## Calamine

| Section | Indications |
| --- | --- |
| Dermatological medicines > Anti-inflammatory and antipruritic medicines<br>◦ Local > Topical > Lotion: | Pruritus |

## Calcipotriol

| Section | Indications |
| --- | --- |
| Dermatological medicines > Medicines affecting skin differentiation and proliferation<br>◦ Local > Topical > Cream: 50 µg per mL (0.005%)<br>◦ Local > Topical > Lotion: 50 µg per mL (0.005%)<br>◦ Local > Topical > Ointment: 50 µg per mL (0.005%) | Psoriasis of unspecified type |

## Calcitriol

| Section | Indications |
| --- | --- |
| Dermatological medicines > Medicines affecting skin differentiation and proliferation | Therapeutic equivalent to calcipotriol for<br>Psoriasis of unspecified type |

## Certolizumab pegol

| Section | Indications |
| --- | --- |
| Dermatological medicines > Medicines affecting skin differentiation and proliferation | Therapeutic equivalent to adalimumab for<br>Psoriasis of unspecified type |

## Ciclopirox

| Section | Indications |
| --- | --- |
| Dermatological medicines > Antifungal medicines<br>◦ Local > Topical > Solution: 80 mg per g (as hydroxypropyl chitosan) | Onychomycosis |

## Coal tar

| Section | Indications |
| --- | --- |
| Dermatological medicines > Medicines affecting skin differentiation and proliferation<br>◦ Local > Topical > Solution: 5% | Psoriasis of unspecified type |

## Etanercept

| Section | Indications |
| --- | --- |
| Dermatological medicines > Medicines affecting skin differentiation and proliferation | Therapeutic equivalent to adalimumab for<br>Psoriasis of unspecified type |

## Fluorouracil

| Section | Indications |
| --- | --- |
| Dermatological medicines > Medicines affecting skin differentiation and proliferation<br>◦ Local > Topical > Ointment: 5% | Plantar warts |

## Glycerol

| Section | Indications |
| --- | --- |
| Dermatological medicines > Moisturizers<br>◦ Local > Topical > Cream: 15 to 20% | Atopic eczema |

## Hydrocortisone

| Section | Indications |
| --- | --- |
| Dermatological medicines > Anti-inflammatory and antipruritic medicines<br>◦ Local > Topical > Cream: 1% (acetate)<br>◦ Local > Topical > Ointment: 1% (acetate) | Dermatitis or eczema<br>Pruritus due to skin disorder<br>Psoriasis of unspecified type<br>Lichen planus |

## Infliximab

| Section | Indications |
| --- | --- |
| Dermatological medicines > Medicines affecting skin differentiation and proliferation | Therapeutic equivalent to adalimumab for<br>Psoriasis of unspecified type |

## Lindane

| Section | Indications |
| --- | --- |
| Dermatological medicines > Scabicides and pediculicides<br>◦ Local > Topical > Cream: 1%<br>◦ Local > Topical > Lotion: 1% | Scabies |

## Methotrexate

| Section | Indications |
| --- | --- |
| Dermatological medicines > Medicines affecting skin differentiation and proliferation<br>◦ Oral > Solid > tablet: 2.5 mg (as sodium salt); 10 mg (as sodium salt) | Psoriasis of unspecified type |

## Miconazole

| Section | Indications |
| --- | --- |
| Dermatological medicines > Antifungal medicines<br>◦ Local > Topical > Cream: 2% (nitrate)<br>◦ Local > Topical > Ointment: 2% (nitrate) | Fungal infection of the skin |

## Mupirocin

| Section | Indications |
| --- | --- |
| Dermatological medicines > Anti-infective medicines<br>◦ Local > Topical > Cream: 2% (as mupirocin calcium)<br>◦ Local > Topical > Ointment: 2% | Superficial bacterial folliculitis<br>Impetigo |

## Permethrin

| Section | Indications |
| --- | --- |
| Dermatological medicines > Scabicides and pediculicides<br>◦ Local > Topical > Lotion: 1%<br>◦ Local > Topical > Cream: 5% | Pediculosis corporis<br>Pediculosis capitis<br>Scabies |

## Podophyllotoxin

| Section | Indications |
| --- | --- |
| Dermatological medicines > Medicines affecting skin differentiation and proliferation | Therapeutic equivalent to podophyllum resin for<br>Plantar warts<br>Therapeutic equivalent to podophyllum resin for<br>Anogenital warts |

## Podophyllum resin

| Section | Indications |
| --- | --- |
| Dermatological medicines > Medicines affecting skin differentiation and proliferation<br>◦ Local > Topical > Solution: 10 to 25% | Plantar warts<br>Anogenital warts |

## Potassium permanganate

| Section | Indications |
| --- | --- |
| Dermatological medicines > Anti-infective medicines<br>◦ Local > Topical > Solution: aqueous solution: 1:10 000 | Tropical phagedaenic ulcer<br>Pemphigus<br>Other specified pyogenic bacterial infection of skin or subcutaneous tissue<br>Impetigo |

## Precipitated sulfur

| Section | Indications |
| --- | --- |
| Dermatological medicines > Scabicides and pediculicides<br>◦ Local > Topical > Ointment: | Therapeutic equivalent to benzyl benzoate for<br>Pediculosis corporis<br>Therapeutic equivalent to benzyl benzoate for<br>Pediculosis capitis<br>Therapeutic equivalent to benzyl benzoate for<br>Pthiriasis<br>Therapeutic equivalent to benzyl benzoate for<br>Scabies |

## Salicylic acid

| Section | Indications |
| --- | --- |
| Dermatological medicines > Medicines affecting skin differentiation and proliferation<br>◦ Local > Topical > Solution: 5% | Seborrhoeic dermatitis<br>Psoriasis of unspecified type<br>Ichthyoses |

## Selenium sulfide

| Section | Indications |
| --- | --- |
| Dermatological medicines > Antifungal medicines<br>◦ Local > Topical > Suspension: 2% detergent-based | Seborrhoeic dermatitis<br>Pityriasis versicolor |

## Silver sulfadiazine

| Section | Indications |
| --- | --- |
| Dermatological medicines > Anti-infective medicines<br>◦ Local > Topical > Cream: 1% | Burns |

## Sodium thiosulfate

| Section | Indications |
| --- | --- |
| Dermatological medicines > Antifungal medicines<br>◦ Local > Topical > Solution: 15% | Pityriasis versicolor |

## Sunscreen, broad-spectrum

| Section | Indications |
| --- | --- |
| Dermatological medicines<br>◦ Topical cream, lotion, gel, ointment, spray with sun protection factor ≥ 50. | Xeroderma pigmentosum |
| Dermatological medicines > Sunscreens<br>◦ Topical:<br>◦ Therapeutic broad-spectrum sunscreens should contain proven active ingredients in appropriate amounts to absorb or filter UVA and UVB radiation, and have a high sun protection factor (SPF). | Albinism or other specified genetically-determined hypomelanotic disorders |

## Tacalcitol

| Section | Indications |
| --- | --- |
| Dermatological medicines > Medicines affecting skin differentiation and proliferation | Therapeutic equivalent to calcipotriol for<br>Psoriasis of unspecified type |

## Terbinafine

| Section | Indications |
| --- | --- |
| Dermatological medicines > Antifungal medicines<br>◦ Local > Topical > Cream: 1% terbinafine hydrochloride<br>◦ Local > Topical > Ointment: 1% terbinafine hydrochloride | Fungal infection of the skin |

## Urea

| Section | Indications |
| --- | --- |
| Dermatological medicines > Medicines affecting skin differentiation and proliferation<br>◦ Local > Topical > Cream: 10%; 5%<br>◦ Local > Topical > Ointment: 10%; 5% | Xerosis cutis or asteatosis |
| Dermatological medicines > Moisturizers<br>◦ Local > Topical > Cream: 5 per % | Atopic eczema |

## Ustekinumab

| Section | Indications |
| --- | --- |
| Dermatological medicines > Medicines affecting skin differentiation and proliferation<br>◦ Parenteral > General injections > SC: 45 mg per 0.5 mL in vial; 45 mg per 0.5 mL in pre-filled syringe; 45 mg per 0.5 mL in pre-filled pen; 90 mg per mL in pre-filled syringe; 90 mg per mL in pre-filled pen | Psoriasis of unspecified type |